NEWS RELEASES
YEAR
-
CANBRIDGE SUBMITS IND APPLICATION FOR CAN008 PhII/III TRIAL IN GBM IN CHINA
JUL 18, 2017
-
James Xue, Founder and CEO of CANbridge, Present at 2017 China GCP Conference
JUN 08, 2017
-
James Xue, Founder and CEO of CANbridge, Present at 2017 Boston CEO Conference
JUN 01, 2017
-
CANBRIDGE LIFE SCIENCES RAISES $25 MILLION IN SERIES B ROUND LED BY LAPAM CAPITAL
MAY 23, 2017
-
CANbridge Life Sciences and Amoy Diagnostics announced that they have entered into a strategic partnership to develop a companion diagnostic assay for CANbridge’s lead candidate, CAN008, a fully human Fc fusion protein.
MAY 08, 2017
-
CANBRIDGE LIFE SCIENCES AWARDED “DEAL OF THE YEAR 2016 ”BY CHINA HEALTHCARE INVESTMENT CONFERENCE FOR LICENSE OF CANCER CANDIDATE FROM AVEO
MAR 31, 2017
-
FIRST PATIENT DOSED IN CANBRIDGE’S CAN-008 PHASE I/II TRIAL IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME IN TAIWAN First CANbridge Clinical Trial
SEP 26, 2016
-
CANBRIDGE SIGNS AGREEMENT WITH BOEHRINGER INGELHEIM TO MANUFACTURE INHIBITORY ANTIBODY,CAN-017, FOR ESOPHAGEAL SQUAMOUS CELL CANCER
AUG 11, 2016
-
CANBRIDGE’S CAN-008 APPROVED FOR PHASE I/II TRIAL IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME IN TAIWAN
JUL 26, 2016
-
CANBRIDGE APPOINTS DR. HUAI ZHONG HU AS VICE PRESIDENT OF PRECLINICAL DEVELOPMENT
JUL 05, 2016
